The Week in Review: Three Life Science Companies to IPO on GEM

Three life science companies will IPO on Shenzhen’s Growth Enterprise Market (GEM), a new Nasdaq-like exchange; AMDL will spin off its China subsidiary Jade Pharma; BioTime will establish a China subsidiary to market its stem cell products in China; China Biologic Products entered an R&D agreement with the Institute of Blood Transfusion of Chengdu; the Mimotopes China & VPSmart-DDS Biodelivery Centers opened its doors in WuXi to develop peptide products; Jiangsu Yanshen Biological Technology was given SFDA approval for its H1N1 flu vaccine; Hualan Biological Bacterin has struck an H1N1 flu vaccine deal with Julphar of the United Arab Emirates; and Tianyin Pharmaceutical announced solid gains in its 2009 fiscal year. More details...  Stock Symbol: (NYSE Alternext US: ADL) (OTCBB: BTIM) (OTCBB: CBPO) (NYSE Amex: TPI)